Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen nominates Peter Guenter to its Board of Directors
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue